Tripping Over TRIPS: Developing Countries’ Access to Lifesaving Medications

By Ashley Cohen and Cassandra Montgomery

After years of pressure, the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) has become a prerequisite for any country if it wishes to join the World Trade Organization (WTO).  TRIPS is an international treaty which globalizes and regulates intellectual property.  Article 31 in the TRIPS Agreement deals with authorized use of patents without the authorization of the patent holder.   In this article we specifically examine some problems and potential solutions of authorized use for emergencies provided for in Article 31.   Many countries sign onto the TRIPS Agreement in order to benefit from joining the WTO.  However, most developing countries are not equipped to meet the demands of the TRIPS Agreement, though they are allowed four years to comply with its requirements.   These third-world countries often need lifesaving drugs they cannot afford to produce themselves and cannot acquire without special provisions.  Consequently, it is necessary to allow special provisions in the TRIPS Agreement to meet the pharmaceutical and health care needs of these developing countries.  New provisions and clarifications are required to remove this barrier to pharmaceutical access. The dilemma lies in how to successfully implement such provisions.